Monte Rosa Therapeutics (GLUE) Change in Account Payables (2020 - 2026)
Monte Rosa Therapeutics (GLUE) posted quarterly Change in Account Payables of $4.4 million for Q1 2026, up 140.25% year-over-year from $1.8 million in Q1 2025, and up 141.25% quarter-over-quarter from -$10.6 million in Q4 2025.
Powered by 
Analysis
Monte Rosa Therapeutics (GLUE) Change in Account Payables (2020 - 2026) Analysis & Trends
Monte Rosa Therapeutics' Change in Account Payables history runs 7 years deep, the most recent figure standing at $4.4 million for Q1 2026.
- In Q1 2026, Change in Account Payables rose 140.25% year-over-year to $4.4 million; the TTM figure through Mar 2026 stood at $1.5 million (up 244.42% YoY), while the FY2025 annual figure was -$13.7 million, down 319.26% from the prior year.
- Change in Account Payables for Q1 2026 stood at $4.4 million, up from -$10.6 million in the prior quarter.
- The five-year high for Change in Account Payables was $13.3 million in Q4 2024, with the low at -$10.9 million in Q1 2025.
- The 5-year median for Change in Account Payables is $155000.0 (2022), against an average of $113823.5.
- The sharpest annual moves came in 2023 and 2024: Change in Account Payables soared 3621.29% in 2023, then slumped 1756.86% in 2024.
- Monte Rosa Therapeutics' Change in Account Payables stood at $155000.0 in 2022, then jumped by 3621.29% to $5.8 million in 2023, then jumped by 130.72% to $13.3 million in 2024, then slumped by 179.74% to -$10.6 million in 2025, then soared by 141.25% to $4.4 million in 2026.
- Business Quant data shows GLUE's Change in Account Payables at $4.4 million in Q1 2026, -$10.6 million in Q4 2025, and $8.9 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn | -8.00 Mn |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | 5.03 Mn |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn | 37.53 Mn |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | - |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | - |
| 10 | Monte Rosa Therapeutics | 1.41 Bn | 781.72 Mn | - | -1.49 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1.49 Mn |
| Mar 31, 2026 | 4.38 Mn |
| Dec 31, 2025 | -10.61 Mn |
| Sep 30, 2025 | 8.88 Mn |
| Jun 30, 2025 | -1.10 Mn |
| Mar 31, 2025 | -10.87 Mn |
| Dec 31, 2024 | 13.31 Mn |
| Sep 30, 2024 | -2.38 Mn |
| Jun 30, 2024 | 394,000.00 |
| Mar 31, 2024 | -5.07 Mn |
| Dec 31, 2023 | 5.77 Mn |
| Sep 30, 2023 | 686,000.00 |
| Jun 30, 2023 | -1.00 Mn |
| Mar 31, 2023 | 306,000.00 |
| Dec 31, 2022 | 155,000.00 |
| Sep 30, 2022 | 1.65 Mn |
| Jun 30, 2022 | -363,000.00 |
| Mar 31, 2022 | -2.18 Mn |
| Dec 31, 2021 | 4.74 Mn |
| Sep 30, 2021 | -4.25 Mn |